• Shopping cart is empty.

    The International Society for Aerosols in Medicine

    Anthony J. Hickey

    Anthony J. Hickey

    Dr. Anthony J. Hickey

    University of North Carolina and RTI International

    Dr. Hickey is Director of the UNC Catalyst for Rare Diseases of the Eshelman School of Pharmacy at the University of North Carolina at Chapel Hill and Distinguished Fellow at RTI International. He received PhD and DSc degrees from the University of Aston in Birmingham. He is a Fellow of AAAS, AAPS and The Royal Societies of Biology and Medicine and founder and officer of Cirrus Pharmaceuticals, Inc., Oriel Therapeutics, Inc. and Astartein, LLC. He received the 2017 Thomas T. Mercer Joint Prize of AAAR and ISAM for excellence in inhaled medicines and pharmaceutical aerosols. His primary research interest is currently the use of aerosols to treat genetic disorders and infectious disease.

    Global Needs in Respiratory Drug Delivery

    Global technology transfer has increased significantly. Consequently, the opportunity to treat lung diseases has expanded. Beyond asthma and COPD, globalization offers a unique opportunity to address pulmonary infectious disease.

    A major effort to explore inhaled therapy for drug-resistant tuberculosis in high burden countries is occurring. Notably these efforts may be facilitated by the efforts to treat drug-resistant non-tuberculous mycobacterial infection with drug aerosols in developed countries.

    Convergence of therapeutic strategies may result in more rapid development with benefits accruing to greater patient populations.